ConductScience.org, home

Paper21396094

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.

Hutcheson IR and 7 others. Breast Cancer Res, 2011. Cited by 46 papers, by iCite.

Cite this record

ConductScience Library. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Papers, record 21396094. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21396094

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.
PubMed
Journal
Breast Cancer Res
PubMed
Year
2011
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
46
iCite
Relative citation ratio, by iCite
0.96
iCite
Revised in PubMed
2021-10-20
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hutcheson IRIain R
2Goddard LLindy
3Barrow DDenise
4McClelland RARichard A
5Francies HEHayley E
6Knowlden JMJanice M
7Nicholson RIRobert I
8Gee JMJulia M W

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ErbB ReceptorsMajor topic
EstradiolMajor topic
Neuregulin-1Major topic
Receptor, ErbB-3Major topic
Breast Neoplasms
Cell Line, Tumor
Cell Proliferation
Cyclin D1
Drug Resistance, Neoplasm
Estrogen Receptor Modulators
Female
Fulvestrant
Humans
Intracellular Signaling Peptides and Proteins
Receptor, ErbB-4
Receptors, Estrogen
Signal Transduction

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in21639949Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4.https://conductscience.org/library/papers/21639949

Source PubMed

Download CSV of comments and corrections

References57

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119609946Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.Int J Cancer2010https://conductscience.org/library/papers/19609946PubMed
217947476Wwox and Ap2gamma expression levels predict tamoxifen response.Clin Cancer Res2007https://conductscience.org/library/papers/17947476PubMed
318270579Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.PLoS One2008https://conductscience.org/library/papers/18270579PubMed
419525314Target-based therapies in breast cancer: current status and future perspectives.Endocr Relat Cancer2009https://conductscience.org/library/papers/19525314PubMed
510698518Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.Oncogene2000https://conductscience.org/library/papers/10698518PubMed
618409071Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.Breast Cancer Res Treat2009https://conductscience.org/library/papers/18409071PubMed
710537315Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.Cancer Res1999https://conductscience.org/library/papers/10537315PubMed
814535532The biology of antihormone failure in breast cancer.Breast Cancer Res Treat2003https://conductscience.org/library/papers/14535532PubMed
915753463Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.J Clin Oncol2005https://conductscience.org/library/papers/15753463PubMed
1011390655Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells.Mol Cell Biol2001https://conductscience.org/library/papers/11390655PubMed
1115084248Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling.Breast Cancer Res2004https://conductscience.org/library/papers/15084248PubMed
1211679632gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase.Science2001https://conductscience.org/library/papers/11679632PubMed
1312820409mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.Anticancer Res2003https://conductscience.org/library/papers/12820409PubMed
148617750HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers.J Biol Chem1996https://conductscience.org/library/papers/8617750PubMed
151333787Expression of the ERBB3 gene product in breast cancer.Br J Cancer1992https://conductscience.org/library/papers/1333787PubMed
1611522647
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
Cancer Res2001https://conductscience.org/library/papers/11522647PubMed
177912565Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.Breast Cancer Res Treat1994https://conductscience.org/library/papers/7912565PubMed
1819481955The upgraded role of HER3 and HER4 receptors in breast cancer.Crit Rev Oncol Hematol2010https://conductscience.org/library/papers/19481955PubMed
199788438c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer.Oncogene1998https://conductscience.org/library/papers/9788438PubMed
208932874Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.Breast Cancer Res Treat1996https://conductscience.org/library/papers/8932874PubMed

See all 57 referencesDownload CSV of references

Cited by34

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.

PMIDTitleJournalYearIn PapersSource
42353156Molecular Mechanisms Underlying Recurrence in Triple-Positive Breast Cancer (ER+/PR+/HER2+) and Potential Repurposing of Multi-Target Inhibitors.Int J Mol Sci2026https://conductscience.org/library/papers/42353156PubMed
41392922Patritumab deruxtecan in breast cancer treatment: a drug evaluation.Future Oncol2025https://conductscience.org/library/papers/41392922PubMed
40908353Patritumab deruxtecan in HR+HER2- advanced breast cancer: a phase 2 trial.Nat Med2025https://conductscience.org/library/papers/40908353PubMed
39995133HER3-targeting Antibody-drug Conjugates Therapy for Solid Tumors: Recent Advances and Future Potentials.Curr Med Chem2026https://conductscience.org/library/papers/39995133PubMed
39020378HER3 receptor and its role in the therapeutic management of metastatic breast cancer.J Transl Med2024https://conductscience.org/library/papers/39020378PubMed
38542136EB1089 Increases the Antiproliferative Response of Lapatinib in Combination with Antiestrogens in HER2-Positive Breast Cancer Cells.Int J Mol Sci2024https://conductscience.org/library/papers/38542136PubMed
38394152Boolean modeling of breast cancer signaling pathways uncovers mechanisms of drug synergy.PLoS One2024https://conductscience.org/library/papers/38394152PubMed
38339304Molecular Atlas of HER2+ Breast Cancer Cells Treated with Endogenous Ligands: Temporal Insights into Mechanisms of Trastuzumab Resistance.Cancers (Basel)2024https://conductscience.org/library/papers/38339304PubMed
37947595HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer.Cells2023https://conductscience.org/library/papers/37947595PubMed
36764093Targeting HER3 for cancer treatment: a new horizon for an old target.ESMO Open2023https://conductscience.org/library/papers/36764093PubMed
36551663HER3 Alterations in Cancer and Potential Clinical Implications.Cancers (Basel)2022https://conductscience.org/library/papers/36551663PubMed
36142451Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer.Int J Mol Sci2022https://conductscience.org/library/papers/36142451PubMed
35254385Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer.Clin Cancer Res2022https://conductscience.org/library/papers/35254385PubMed
33608318Thirty Years of HER3: From Basic Biology to Therapeutic Interventions.Clin Cancer Res2021https://conductscience.org/library/papers/33608318PubMed
33500629Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib-Irinotecan Combo: A Case Study.Onco Targets Ther2021https://conductscience.org/library/papers/33500629PubMed
33420373A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance.Oncogene2021https://conductscience.org/library/papers/33420373PubMed
33176725Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.BMC Cancer2020https://conductscience.org/library/papers/33176725PubMed
31756933Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials.Cancers (Basel)2019https://conductscience.org/library/papers/31756933PubMed
31519989ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.Oncogene2020https://conductscience.org/library/papers/31519989PubMed
30314968Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.Clin Cancer Res2019https://conductscience.org/library/papers/30314968PubMed

See all 34 cited byDownload CSV of cited by

Genes16

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21396094

GET https://conductscience.org/api/papers/v1/21396094/references?page=2